Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
4/5 보강
TL;DR
LDOM has a good safety profile as a treatment for hair loss and systemic adverse effects were infrequent and only 1.7% of patients stopped the treatment due to adverse effects.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
1404 patients (943 women [67.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] LDOM has a good safety profile as a treatment for hair loss. Systemic adverse effects were infrequent and only 1.7% of patients discontinued treatment owing to adverse effects.
📑 코퍼스 인용 관계
· 인용됨 45
📑 인용한 논문 (6) ▾
- Sustainability of functional hair follicle activity: Impact of spatially anchored multifun… Bioactive materials · 2026
- Low-Dose Oral Minoxidil Improves Hairline and Eyebrow Coverage in Frontal Fibrosing Alopec… Dermatology and therapy · 2026
- A Critic of Retrospective Multicenter Studies in Clinical Trichology. International journal of trichology · 2025
- Secondary Cutis Verticis Gyrata Induced by Long-Term Use of High-Dose Topical Minoxidil. Skin appendage disorders · 2025
- Gender Differences in Adverse Effects and Dosing Practices of Low-Dose Oral Minoxidil for … Skin appendage disorders · 2025
- Low-Dose Oral Minoxidil during Chemotherapy: A Review of the Mechanism and Current Evidenc… Skin appendage disorders · 2025
연도별 인용 (2012–2026) · 합계 168
OpenAlex 토픽 ·
Hair Growth and Disorders
Facial Rejuvenation and Surgery Techniques
Acne and Rosacea Treatments and Effects
Abstract 🌐 Abstract
[BACKGROUND] The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects.
[OBJECTIVE] To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients.
[METHODS] Retrospective multicenter study of patients treated with LDOM for at least 3 months for any type of alopecia.
[RESULTS] A total of 1404 patients (943 women [67.2%] and 461 men [32.8%]) with a mean age of 43 years (range 8-86) were included. The dose of LDOM was titrated in 1065 patients, allowing the analysis of 2469 different cases. The most frequent adverse effect was hypertrichosis (15.1%), which led to treatment withdrawal in 14 patients (0.5%). Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%), and insomnia (0.2%), leading to drug discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed.
[LIMITATIONS] Retrospective design and lack of a control group.
[CONCLUSION] LDOM has a good safety profile as a treatment for hair loss. Systemic adverse effects were infrequent and only 1.7% of patients discontinued treatment owing to adverse effects.
[OBJECTIVE] To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients.
[METHODS] Retrospective multicenter study of patients treated with LDOM for at least 3 months for any type of alopecia.
[RESULTS] A total of 1404 patients (943 women [67.2%] and 461 men [32.8%]) with a mean age of 43 years (range 8-86) were included. The dose of LDOM was titrated in 1065 patients, allowing the analysis of 2469 different cases. The most frequent adverse effect was hypertrichosis (15.1%), which led to treatment withdrawal in 14 patients (0.5%). Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%), and insomnia (0.2%), leading to drug discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed.
[LIMITATIONS] Retrospective design and lack of a control group.
[CONCLUSION] LDOM has a good safety profile as a treatment for hair loss. Systemic adverse effects were infrequent and only 1.7% of patients discontinued treatment owing to adverse effects.
LDOM has a good safety profile as a treatment for hair loss and systemic adverse effects were infrequent and only 1.7% of patients stopped the treatment due to adverse effects.
APA 7
S, V., Pirmez, R., Hermosa-Gelbard, A., ÓM, M., Saceda-Corralo, D., Rodrigues-Barata, R., Jimenez-Cauhe, J., Koh, W. L., Poa, J. E., Jerjen, R., L, T. d. C., John, J. M., Salas-Callo, C. I., Vincenzi, C., Yin, L., Lo-Sicco, K., Waskiel-Burnat, A., Starace, M., Zamorano, J. L., P, J., & ... (2021). Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.. Journal of the American Academy of Dermatology, 84(6), 1644-1651. https://doi.org/10.1016/j.jaad.2021.02.054
Vancouver
S V, Pirmez R, Hermosa-Gelbard A, ÓM M, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Jour. Amer. Acad. Derm.. 2021;84(6):1644-1651. doi:10.1016/j.jaad.2021.02.054
AMA 11
S V, Pirmez R, Hermosa-Gelbard A, ÓM M, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Jour. Amer. Acad. Derm.. 2021;84(6):1644-1651. doi:10.1016/j.jaad.2021.02.054
Chicago
S, V., Pirmez, R., Hermosa-Gelbard, A., ÓM, M., Saceda-Corralo, D., Rodrigues-Barata, R., Jimenez-Cauhe, J., Koh, W. L., Poa, J. E., Jerjen, R., and .... 2021. "Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients." Journal of the American Academy of Dermatology 84 (6): 1644-1651. https://doi.org/10.1016/j.jaad.2021.02.054
MLA 9
S, V., et al. "Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients." Journal of the American Academy of Dermatology, vol. 84, no. 6, 2021, pp. 1644-1651. doi:10.1016/j.jaad.2021.02.054.
PMID
33639244 ↗
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 약물 | minoxidil
|
미녹시딜 | dict | 2 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Administration
- Oral
- Adolescent
- Adult
- Aged
- 80 and over
- Alopecia
- Child
- Dizziness
- Edema
- Female
- Headache
- Humans
- Hypertrichosis
- Male
- Middle Aged
- Minoxidil
- Retrospective Studies
- Sleep Initiation and Maintenance Disorders
- Tachycardia
- Young Adult
- alopecia
- androgenetic alopecia
- arterial hypotension
… 외 13개
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considera…
- Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature.
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs.
- Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alo…
- Advances in hair growth.
- Oral minoxidil use in androgenetic alopecia and telogen effluvium.
- Permanent chemotherapy-induced alopecia after hematopoietic stem cell transplantation treated with l…
- Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review.
- Oral minoxidil for late alopecia in cancer survivors.
- Serious complication of low-dose oral minoxidil for hair loss.
- Role of Oral Minoxidil in Patterned Hair Loss.
- Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia:…
- Oral Supplementation with l-Cystine, , , and in Chronic Telogen Effluvium and Androgenetic Alopecia…
- Combating "dread shed": The impact of overlapping topical and oral minoxidil on temporary hair shedd…
- Letter in reply: Pericarditis and peripheral edema in a healthy man on low-dose oral minoxidil thera…
- Mechanisms and clinical progress of adipose-derived stem cells and their derivatives in the treatmen…
- The Role of Patient- and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses o…
- Low-Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting S…
- Dermatologists' Knowledge, Attitude, and Practice Pattern Toward Low-Dose Oral Minoxidil in Hair Los…
- Increased Interest in Oral Minoxidil for Hair Loss Treatment Following Publication of August 2022 Ne…
같은 제1저자의 인용 많은 논문 (5)
- Frontal fibrosing alopecia: a multicenter review of 355 patients.
- Frequency of the Types of Alopecia at Twenty-Two Specialist Hair Clinics: A Multicenter Study.
- Updated diagnostic criteria for frontal fibrosing alopecia.
- Oral minoxidil improves background hair thickness in lichen planopilaris.
- Hair transplant in frontal fibrosing alopecia: A multicenter review of 51 patients.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 미국 임상내분비학회, 미국 내분비학회, 안드로겐 과다 및 PCOS 학회 질환 임상 리뷰: 다낭성 난소 증후군의 평가와 치료를 위한 최선의 진료 지침--1부.
- 임상 진료. 다낭성 난소 증후군.
- PCOS의 유전적, 호르몬적, 대사적 측면: 최신 동향.
- Rochester Epidemiology Project(1990-2009)에서 추정된 원형 탈모의 평생 발병 위험도는 2.1%이다.
- 폐경전 여성의 다모증 평가 및 치료: Endocrine Society 임상진료지침.
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Minoxidil and its use in hair disorders: a review.
TL;DRThis article aims to review and update current information on the pharmacology, mechanism of action, clinical efficacy, and adverse events of topical minoxidil.
-
Androgenetic Alopecia: Therapy Update.
TL;DRThis comprehensive review discusses the evaluation of AGA and the mechanisms of action, costs, efficacies, and safety profiles of existing, alternative, and upcoming therapeutics f…
-
Treatment of alopecia areata: An Australian expert consensus statement.
TL;DRThe purpose of this consensus statement is to outline a treatment algorithm for AA, including the indications for systemic treatment, appropriate choice of systemictreatment, satis…
-
Telogen Effluvium: A Review of the Literature.
TL;DRIn the treatment of telogen effluvium, it is essential to identify and remove the causative factors and to use drugs such as corticosteroids, minoxidil, and novel treatments such a…